#Japan #Seoul #Boostimmune #TCTP #MDSC

Boostimmune Secures Japanese Patent for TCTP Antibody Technology

In a significant milestone for cancer therapy, Boostimmune has obtained a Japanese patent that covers their innovative technology utilizing antibodies to inhibit the translationally controlled tumor protein (TCTP) that is released from dead tumor cells. This breakthrough is pivotal in suppressing the accumulation of myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment, which are known to hinder antitumor immune responses.

Understanding TCTP and MDSC Interaction

The recently granted patent isn't limited by specific antibody sequences or configurations. Instead, it emphasizes the functional capabilities of an anti-TCTP antibody that effectively reduces MDSC aggregation within tumors. Importantly, Boostimmune's technology addresses two crucial aspects—limiting polymorphonuclear MDSCs (PMN-MDSCs) and advancing cancer therapeutic strategies with compositions that include these inhibitors.

When tumor cells die, TCTP can leak into the extracellular space and interact with nearby immunosuppressive myeloid cells, essentially promoting an environment conducive to cancer progression. This is where Boostimmune's approach shines: by developing antibodies that block TCTP's functions, they aim to curtail MDSC accumulation, thereby potentially reinstating the body’s natural immune response against tumors.

Strengthening Intellectual Property and Future Applications

The patent underscores Boostimmune's robust intellectual property standing in Japan for its lead candidate, BIO101, which is intrinsically designed to modulate the immune system's interaction with tumor microenvironments. With this patent in hand, the company is solidifying its path toward clinical development in Japan, aiming to establish collaborative relationships with pharmaceutical and biotech enterprises worldwide.

The work surrounding BIO101 is grounded in pivotal research led by Professor Tadatsugu Taniguchi from the University of Tokyo, who is also a co-founder of Boostimmune. His team's findings, published in prestigious journals such as Nature Immunology, revealed the crucial role of TCTP in promoting the accumulation of MDSCs, thus validating the therapeutic potential of targeting this pathway.

Future Directions

Dr. Gwanghee Lee, CEO of Boostimmune, highlighted the significance of this patent, stating, "The granted claims are centered on the function of inhibiting TCTP released from dead tumor cells to suppress MDSC accumulation in tumors, as well as associated therapeutic applications." This focus on function rather than sequence broadens the scope for developing various antibodies that could fit into this therapeutic model.

With this patent, Boostimmune is not only focusing on advancing BIO101 but is also strategically positioning itself for further breakthroughs in cancer immunotherapy. The implications are vast, as the technique could lead to new therapeutic compositions that utilize TCTP antibody functionality to transform cancer treatment paradigms. As such, this Japanese patent is a significant step toward advancing cancer therapeutics, ensuring that Boostimmune remains at the forefront of an evolving medical landscape.

In summary, Boostimmune's patented technology represents a potent tool in immuno-oncology. The proactive approach to regulating the immunosuppressive environment in tumors through TCTP modulation could herald new hope for effective cancer therapies.